ArticleCost effectiveness and resource allocation : C/E2026
Cost-utility analysis of Edaravone compared to Riluzole in patients with amyotrophic lateral sclerosis (ALS) in Iran.
Habib Omranikhoo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.